Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy
The administration of oral versus IV decitabine is expected to generate cost savings for the Italian NHS in terms of drug administration, CVC and infection management, in patients with AML ineligible for induction chemotherapy.
Authors
- F Fiorentino (ORCID: https://orcid.org/0000-0003-2092-3593)
- Chiara Vassallo (ORCID: https://orcid.org/0000-0001-5811-5992)
- Loreto Spencer L. (ORCID: https://orcid.org/0009-0004-0322-5798)
- Angelo Costanzo (ORCID: https://orcid.org/0009-0007-5528-138X)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/ceor.s495401
- Citations
- 2
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Otsuka Pharmaceutical